Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

SUMMARY: The RisedronatE and ALendronate (REAL) study provided a unique opportunity to conduct cost-effectiveness analyses based on effectiveness data from real-world clinical practice. Using a published osteoporosis model, the researchers found risedronate to be cost-effective compared to generic o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Osteoporos Int
Autori principali: Grima, D. T., Papaioannou, A., Thompson, M. F., Pasquale, M. K., Adachi, J. D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2007
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104544/
https://ncbi.nlm.nih.gov/pubmed/18008100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-007-0504-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi